»
«
Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED

China Ibandronate sodium monohydrate CAS 138926-19-9 Ibandrate Ibandromate Monosodium Bonviva manufacturer

5th

Gold Index: 89134

You are here: home  > Pharmaceutical Chemicals API  > Antineoplastic Drugs API  > Ibandronate sodium monohydrate CAS 138926-19-9 Ibandrate Ibandromate Monosodium Bonviva

Ibandronate sodium monohydrate CAS 138926-19-9 Ibandrate Ibandromate Monosodium Bonviva 

Payment Terms: T/T,L/C,WU 
Place of Origin: Zhejiang, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: MOSINTER
Production Capacity: 10 Ton/year
Delivery Date: within 7 days
Molecular Weight: 359.23
Appearance: White crystalline powder
Means of Transport: Ocean,Land,Air
Packing: According to the request of...
Molecular Formula: C9H24NNaO8P2
Specification: CP/USP/EP
Melting point: 840℃ (dec)

It is known that biphosphonates bind strongly to hydroxyapatite crystals at the sites of increased bone turnover preferentially

Ibandronate sodium monohydrate( CAS: 138926-19-9)


Item

Index

Molecular Formula

C9H24NNaO8P2

Molecular Weight

359.23

Specification

CP/USP/EP

Appearance

White crystalline powder

Melting point

840℃ (dec)


Biphosphonate, a salt, ester, or anion of a dimer of phosphonic acid (diphosphonic acid), inhibits bone resorption as a sodium salt and complexed with technetium Tc 99m for bone imaging. The monophosphonates are not active. Biphosphonates are used in disorders affecting the skeleton such as osteoporosis, metastatic disease, and Paget's disease. While bisphosphonates are analogues of endogenous pyrophosphate structurally, they are characterized by a P-C-P bond, the linking oxygen is replaced with a carbon, which is resistant to enzymatic and chemical hydrolysis. General structure is Side chains are responsible for chemical-physicla properties, mechanism of resorption, and pharmacokinetics. It is known that biphosphonates bind strongly to hydroxyapatite crystals at the sites of increased bone turnover preferentially and inhibit the formation, aggregation, and dissolution of the crystals.They also may inhibit osteoclast function directly, promotion of osteoclast apoptosis, and interference with osteoblast-mediated osteoclast activation.

Medication members for the treatment of postmenopausal osteoporosis in women by building healthy bone and restoring some of the bone loss as a result of osteoporosis include vitamin D and calcium supplements, bisphosphonate drugs, certain selective estrogen receptor modulators, estrogen replacements and parathyroid hormones. 

bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

sgs ico Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: